Rationale for the Clinical use of Immunotoxins: Monoclonal Antibodies Conjugated to Ribosome-Inactivating Proteins

References

• Gale R. P., Champlin R. E. Bone marrow transplantation in acute leukemia. Clinics in Hematology 1986; 15: 851–872
   PubMedGoogle Scholar
• Champlin R., Gale R. P. Bone marrow transplantation for acute leukemia: recent advances and comparison with alternative therapies. Seminars in Hematology 1987; 24: 55–67
   PubMed Web of Science ®Google Scholar
• Anderson J., Krivit W., Chilcote R., Pyesmany A., Chard R., Hammond D. Comparison of the therapeutic response of patients with childhood acute lymphoblastic Leukemia in relapse to vindesine verus vincristine in combination with prednisone and L-asparaginase: a phase III trial. Cancer Treatment Reports 1981; 65: 1015–1019
   PubMedGoogle Scholar
• Rivera G., Murphy S. B., Aur R. J. A. Recurrent childhood lymphocytic leukemia: clinical and cytokinetic studies of cytosine arabinoside and methotrexate for maintenance of second hematologic remission. Cancer 1978; 42: 2521–2528
   PubMed Web of Science ®Google Scholar
• Bortin M. M., Horowitz M. M., Rimm A. A. Report from the International Bone Marrow Transplant Registry. Bone Marrow Transplantation 1989; 4: 221–228
   PubMed Web of Science ®Google Scholar
• Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–497
   PubMed Web of Science ®Google Scholar
• Ehrlich P. The relationship existing between chemical consitution, distribution, and pharmacological action. The collected papers of Paul Ehrlich, F. Himmelweite. Pergamon, Elmsford, NY 1956; Vol. 1: 596–618
   Google Scholar
• Buchsbaum D. J., Wahl R. L., Glenn S. D., Normolle D. P., Kaminski M. S. Improved delivery of radiolabeled anti-Bl monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-Bl monoclonal antibody. Cancer Research 1992; 52: 637–642
   PubMed Web of Science ®Google Scholar
• Dullens H. F. J., Vennegoor C., Deweger R. A., Den Otter W. Antitumour effect of chlorambucil antibody complexes in a murine melanoma system. European Journal of Cancer 1979; 151: 69–75
   Web of Science ®Google Scholar
• Xie S., Inazawa M., Sinha N., Sawada S., Vergidis R., Diener E. Facilitation of allogeneic bone marrow transplantation by a T cell-specific immunotoxin containing daunomycin. Transplantation 1987; 44: 770–774
   PubMed Web of Science ®Google Scholar
• Larson S. Cancer Research 1990; 1989: 892s–898s, Clinical radioimmunodetection, 1978–: overview and suggestions for standardization of clinical trials., 50
   Google Scholar
• Stirpe F., Barbieri L. Ribosome-inactivating proteins up to date. Federation of European Biochemical Society 1986; 195: 1–8
   PubMed Web of Science ®Google Scholar
• Ferrari C., Barbieri L., Stirpe F. Effects of plant ribosome-inactivating proteins on ribosomes from Musca domestica. Comparative Biochemistry and Physiology 1991; 100B: 223–227
   Google Scholar
• Eiklid K., Olsnes S., Pihl A. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Experimental Cell Research 1980; 126: 321–326
   PubMed Web of Science ®Google Scholar
• Olsnes S., Pihl A. Toxic lectins and related proteins. Molecular action of toxins and viruses, P. Cohen, S. van Heyningen. Elseviers Biomedical Press, Amsterdam 1982; 51–105
   Google Scholar
• Endo Y., Tsurugi K. RNA N-glycosidase activity of ricin A chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. Journal Biological Chemistry 1987; 262: 8128–8130
   PubMed Web of Science ®Google Scholar
• Collier R. J., In A. Immunotoxins, A. E. Frankel. Kluwer Academic Publishers, Boston 1988; 25–35
   Google Scholar
• Endo Y., Huber P., Wool I. The ribonuclease activity of the cytotoxin alpha-sarcin cleavage site in rat 28S ribosomal ribonucleic acid. Journal of Biological Chemistry 1983; 258: 2662–2667
   PubMedGoogle Scholar
• Ogata M., Chaudhary V. K., Pastan I., FitzGerald D. J. Processing of Pseudomonas exotoxin by a cellular protease resulting in the generation of a 37,000 Da toxin fragment that is translocated to the cytosol. Journal of Biological Chemistry 1990; 265: 20678–20685
   PubMed Web of Science ®Google Scholar
• Williams D. P., Snider C. E., Strom T. B., Murphy J. R. Structure/function analysis of interleukin-2-toxin (DAB486-IL2). Journal of Biological Chemistry 1990; 265: 11885–11889
   PubMed Web of Science ®Google Scholar
• Olsnes S., Sandvig K. Entry of polypeptide toxins into mammalian cells. Endocytosis., I. Pastan, M. C. Willingham. Plenum Press, New York 1985; 195–234
   Google Scholar
• Olsnes S., Pihl A. Chimeric toxins. Pharmacology and Therapy 1982; 15: 355–382
   Web of Science ®Google Scholar
• Fong W. P., Wong R. N. S., Go T. T. M., Yeung H. W. Enzymatic properties of ribosome-inactivating proteins (RIPs) and related toxins. Life Sciences 1991; 49: 1859–1869
   PubMed Web of Science ®Google Scholar
• Rybak S. M., Youle R. J. Clinical use of immunotoxins. Monoclonal antibodies conjugated to protein toxins. Immunology and Allergy Clinics of North America 1991; 11: 359–380
   Web of Science ®Google Scholar
• Thorpe P. E. Antibody carriers of cytotoxic agents in cancer therapy: A review. Monoclonal antibodies ' 84: Biological and clinical applications, A. Pinchera, G. Doria, F. Dammacco, A. Bargellesi. Editrice Kurds s.r.l., Miland 1985; 475–512
   Google Scholar
• Leonard J. E., Taetle R., To D., Rhyner K. Preclinical studies on the use of selective antibody-ricin conjugates in autologous bone marrow transplantation. Blood 1985; 65: 1149–1157
   PubMed Web of Science ®Google Scholar
• Thorpe P. E., Cumber A. J., Williams N., Edwards D. C., Ross W. C. J., Davies A. J. S. Abrogation of the non-specific cytotoxicity of abrin conjugated to anti-lymphocyte globulin. Clinical Experimental Immunology 1981; 43: 195–200
   PubMed Web of Science ®Google Scholar
• Stong R. C., Youle R. J., Vallera D. A. Elimination of clonogenic T-leukemic cells from human bone marrow using anti-Mr 65,000 protein immunotoxins. Cancer Research 1984; 44: 3000–3006
   PubMed Web of Science ®Google Scholar
• Colombatti M., Johnson V. G., Skopicki H. A., Fendley B., Lewis M. S., Youle R. J. Identification and characterization of a monoclonal antibody recognizing a galactose-binding domain of the toxin ricin. Journal of Immunology 1987; 138: 3339–3344
   PubMed Web of Science ®Google Scholar
• Pietersz G. A., Kanellos J., McKenzie I. F. C. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity. Cancer Research 1988; 48: 4469–4476
   PubMed Web of Science ®Google Scholar
• Wawrzynczak E. J., Watson G. J., Cumber A. J., Henry R. V., Parnell G. D., Rieber E. P., Thorpe P. E. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A-chain immunotoxin potentiated with ricin B chain or with a ricin B-chain immunotoxin. Cancer Immunology and Immunotherapy 1991; 32: 289–295
   PubMed Web of Science ®Google Scholar
• Vitetta E. S., Yen N. Expression and functional properties of genetically engineered ricin B chain lacking galactose-binding activity. Biochimica et Biophysica Acta 1990; 1049: 151–157
   PubMed Web of Science ®Google Scholar
• Jansen F. K., Blythman H. E., Carriere D., Casellas P., Gros O., Gros P., Laurent J. C., Paolucci F., Pau B., Poncelet P., Richer G., Vidal H., Voisin G. A. Immunotoxins: Hybrid molecules combining specificity and potent cytotoxi-city. Immunology Reviews 1982; 62: 185–216
   PubMed Web of Science ®Google Scholar
• Olsnes S., Pihl A. Different biological properties of the two constituent peptide chains of ricin, a toxic protein inhibiting protein synthesis. Biochemistry 1973; 12: 3121–3126
   PubMed Web of Science ®Google Scholar
• Seetharam S., Chaudhary V. K., FitzGerald D., Pastan I. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. Journal of Biological Chemistry 1991; 266: 17376–17381
   PubMed Web of Science ®Google Scholar
• Greenfield L., Johnson V. G., Youle R. J. Point mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 1987; 238: 536–539
   PubMed Web of Science ®Google Scholar
• Lambert J. M., Goldmacher V. S., Collinson A. R., Nadler L. M., Blattler W. A. An immunotoxin prepared with blocked ricin: A natural plant toxin adapted for therapeutic use. Cancer Research 1991; 51: 6236–6242
   PubMed Web of Science ®Google Scholar
• Derocq J.-M., Laurent G., Casellas P., Vidal H., Poncelet P., Fauser A. A., Demur C., Jansen F. K. Rationale for the selection of ricin A-chain anti-T immunotoxins for mature T cell depletion. Transplantation 1987; 44: 763–769
   PubMed Web of Science ®Google Scholar
• Till M., May R. D., Uhr J. W., Thorpe P. E., Vitetta E. S. An assay that predicts the ability of monoclonal antibodies to form potent ricin A-chain-containing immunotoxins. Cancer Research 1988; 48: 1119
   PubMed Web of Science ®Google Scholar
• Preijers F. W. M. B., Tax W. J. M., De Witte T. J. M., Janssen A., Van der Heijden H., Vidal H., Wessels J. M. C., Capel P. J. A. Relationship between internaliza-tion and cytotoxicity of ricin A-chain immunotoxins. British Journal of Haematology 1988; 70: 289–294
   PubMed Web of Science ®Google Scholar
• Luo Y., Seon B. K. Marked difference in the in vitro antitumor efficacy between two immunotoxins targeted to different epitopes of common acute lymphoblastic Leukemia antigen (CD10). Journal of Immunology 1990; 145: 1974–1982
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Jaszcz W., Ambrus J. L., Fauci A. S., Gajl-Peczalska K., Song C. M., Wick M. R., Myer D. E., Waddick K., Ledbetter J. A. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 1988; 71: 13–29
   PubMed Web of Science ®Google Scholar
• Shen G.-L., Li J.-L., Ghetie M.-A., May R. D., Till M., Brown A. N., Relf M., Knowles P., Uhr J. W., Janossy G., Amlot P., Vitetta E. S., Thorpe P. E. Evaluation of four CD22 antibodies as ricin A-chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. International Journal of Cancer 1988; 42: 792–797
   PubMed Web of Science ®Google Scholar
• Barbieri L., Bolognesi A., Dinota A., Lappi D. A., Soria M., Tazzari P. L., Stirpe F. Selective killing of CD4 + and CD8 + cells with immunotoxins containing saporin. Scandinavian Journal of Immunology 1989; 30: 369–372
   PubMed Web of Science ®Google Scholar
• Madshus I. H., Stenmark H., Sandvig K., Olsnes S. Entry of diphtheria toxin-protein A chimeras into cells. Journal of Biological Chemistry 1991; 266: 17446–17453
   PubMed Web of Science ®Google Scholar
• Chignola R., Colombatti M., Dell'Arciprete Candiani C., Tridente G. Distribution of endocytosed molecules to intracellular acidic environments correlates with immunotoxin activity. International Journal of Cancer 1990; 46: 1117–1123
   PubMed Web of Science ®Google Scholar
• Blum J. S., Fiani M. L., Stahl P. D. Proteolytic cleavage of ricin A chain in endosomal vesicles. Evidence for the action of endosomal proteases at both neutral and acidic pH. Journal of Biological Chemistry 1991; 266: 22091–22095
   PubMed Web of Science ®Google Scholar
• Hudson T. H., Grillo F. G. Brefeldin-A enhancement of ricin A-chain immunotoxins and blockade of intact ricin, modeccin, and abrin. Journal of Biological Chemistry 1991; 266: 18586
   PubMed Web of Science ®Google Scholar
• Press O. W., Vitetta E. S., Farr A. G., Hansen J. A., Martin P. J. Evaluation of ricin A-chain immunotoxins directed against human T cells. Cellular Immunology 1986; 102: 10–20
   PubMed Web of Science ®Google Scholar
• Casellas P., Bourrié B. J. P., Gros P., Jansen F. K. Kinetics of cytotoxicity induced by immunotoxins: enhancement by lysosomotropic amines and carboxylic ionophores. Journal of Biological Chemistry 1984; 259: 9359–9364
   PubMed Web of Science ®Google Scholar
• Colombatti M., Dellarciprete L., Chignola R., Tridente G. Carrier protein-monensin conjugates-enhancement of immunotoxin cytotoxicity and potentiating treatment. Cancer Research 1990; 50: 1385–1391
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S., Bjorn M. J., Houston L. L. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds. Cancer Research 1989; 49: 613–617
   PubMed Web of Science ®Google Scholar
• Press O. W., DeSantes K., Anderson S. K., Geissler F. Inhibition of catabolism of radiolabeled antibodies by tumor cells using lysosomotropic amines and carboxylic ionophores. Cancer Research 1990; 50: 1243–1250
   PubMed Web of Science ®Google Scholar
• Von Figura K., Steckel F., Hasilik A. Juvenile and adult metachromatic leukodystrophy: Partial restoration of arylsulfatase A (cerebroside sulfatase) activity by inhibitors of thiol proteinases. Proceedings of the National Academy of Science of the USA 1983; 80: 6066–6070
   PubMed Web of Science ®Google Scholar
• Ohkuma S., Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proceedings of the National Academy of Science of the USA 1978; 75: 3327–3331
   PubMed Web of Science ®Google Scholar
• Preijers F. W. M. B., De Witte T., Wessels J. M. C., Meyerink J. P. P., Haanen C., Capel P. J. A. Cytotoxic potential of anti-CD7 immunotoxin (WT1-ricin A) to purge ex vivo malignant T cells in bone marrow. British Journal of Haematology 1989; 71: 195–201
   PubMed Web of Science ®Google Scholar
• Van Deurs B., Petersen O. W., Olsnes S., Sandvig K. Delivery of internalized ricin from endosomes to cisternal Golgi elements is a discontinuous, temperature-sensitive process. Experimental Cell Research 1987; 171: 137–152
   PubMed Web of Science ®Google Scholar
• Wright H. T., Robertus J. D. The intersubunit disulfide bridge of ricin is essential for cytotoxicity. Archives of Biochemistry and Biophysics 1987; 256: 280–284
   PubMed Web of Science ®Google Scholar
• Ghetie V., Till M. A., Ghetie M.-A., Tucker T., Porter J., Patzer E. J., Richardson J. A., Uhr J. W., Vitetta E. S. Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin A chain using different cross-linkers. Bioconjugate Chemistry 1990; 1: 24–31
   PubMed Web of Science ®Google Scholar
• Masuho Y., Kishida K., Saito M., Umemoto N., Hara T. Importance of the antigen-binding valency and the nature of the cross-linking bond in ricin A-chain conjugates with antibody. Journal of Biochemistry 1982; 91: 1583–1591
   PubMed Web of Science ®Google Scholar
• Carlsson J., Drevin H., Axen R. Protein thiolation and reversible protein-protein conjugation. N-succinimidyl 3(2-pyridyldithio) propionate, a new hetero-bifunctional reagent. Biochemical Journal 1978; 173: 723–737
   PubMed Web of Science ®Google Scholar
• Thorpe P. E., Blakey D. C., Brown A. N. F., Knowles P. P., Knyba R. E., Wallace P. J., Watson G. J., Wawrzynczak E. J. Comparison of two anti-Thy 1.1 abrin A-chain immunotoxins prepared with different cross-linking agents: antitumour effects, in vivo fate, and tumor cell mutants. Journal of the National Cancer Institute 1987; 79: 1101–1112
   PubMed Web of Science ®Google Scholar
• Kersey J. H., Weisdorf D., Nesbit M. E., LeBien T. W., Woods W. G., McGlave P. B., Kim T., Vallera D. A., Goldman A. I., Bostrom B., Hurd D., Ramsay N. K. C. Comparison of autologous and aliogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. New England Journal of Medicine 1987; 317: 461–467
   PubMed Web of Science ®Google Scholar
• Appelbaum F. R., Buckner C. D. Overview of the clinical relevance of autologous bone marrow transplantation. Clinics in Hematology 1986; 15: 118
   Google Scholar
• Report of an international Cooperative Study. Bone-marrow autotransplantation in man. Lancet 1986; 2: 960–962
   PubMed Web of Science ®Google Scholar
• Takvorian T., Canellos G. P., Ritz J., Freedman A. S., Anderson K. C., Mauch P., Tarbell N., Coral F., Daley H., Yeap B., Schlossman S. F., Nadler L. M. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. New England Journal of Medicine 1987; 316: 1499–1505
   PubMed Web of Science ®Google Scholar
• Philip T., Armitage J. O., Spitzer G., Chauvin F., Jagannath S., Cahn J.-Y., Colombat P., Goldstone A. H., Gorin N. C., Flesh M., Laporte J.-P., Maraninchi D., Pico J., Bosly A., Anderson D., Schots R., Biron P., Cabanillas F., Dicke K. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. New England Journal of Medicine 1987; 316: 1493–1498
   PubMed Web of Science ®Google Scholar
• Gorin N. C., Aegerter P., Auvert B., Meloni G., Goldstone A. H., Burnett A., Carella A., Korbling M., Herve P., Maraninchi D., Lowenberg R., Verdonck L. F., de Planque M., Hermans J., Helbig W., Porcellini A., Rizzoli V., Alesandrino E. P., Franklin I. M., Reiffers J., Colleselli P., Goldman J. M. Bone marrow transplantation for acute myelocytic Leukemia in first remission: A European survey of the role of marrow purging. Blood 1990; 75: 1606–1614
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Kersey J. H., Vallera D. A., Ledbetter J. A., Weisdorf D., Myers D. E., Haake R., Ramsay N. K. C. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic Leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging. Blood 1990; 76: 1723–1733
   PubMed Web of Science ®Google Scholar
• Rowley S. D., Piantadosi S., Santos G. W. Correlation of hematologic recovery with CFU-GM content of autologous bone marrow grafts treated with 4-hydroperoxycyclophosphamide. Culture after cryopreservation. Bone Marrow Transplantation 1989; 4: 553–558
   PubMed Web of Science ®Google Scholar
• Bast R. C., Jr, De Fabritis P., Lipton J., Gelber R., Maver C., Nadler L., Sallan S., Ritz J. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Research 1985; 45: 499–503
   PubMed Web of Science ®Google Scholar
• Slaper-Cortenbach I. C., Admiraal L. G., van Leeuwen E. F., Kerr J. M. Effective purging of bone marrow by a combination of immunorosette depletion and complement lysis. Experimental Hemalology 1990; 18: 49–54
   PubMed Web of Science ®Google Scholar
• Howell A. L., Ball E. D. Monoclonal antibody-mediated cytotoxicity of human myeloid Leukemia cells: an vitro model for estimating efficiency and optimal conditions for cytolysis. Blood 1985; 66: 649–654
   PubMed Web of Science ®Google Scholar
• Preijers F. W. M. B., De Witte T., Rijke-Schilder G. P. M., Tax W. J. M., Wessels J. M. C., Haanen C., Capel P. J. A. Human T lymphocyte differentiation antigens as target for immunotoxins or complement mediated cytotoxicity. Scandinavian Journal of Immunology 1988; 28: 185–194
   PubMed Web of Science ®Google Scholar
• Reading C. L., Takaue Y. Monoclonal antibody applications in bone marrow transplantation. Biochimica et Biophysica Acta 1986; 865: 141–154
   PubMed Web of Science ®Google Scholar
• Casellas P., Canat X., Fauser A. A., Gros O., Laurent G., Poncelet P., Jansen J. Optimal elimination of leukemic cells from bone marrow with T1O1-ricin A-chain immunotoxin. Blood 1985; 65: 289–297
   PubMed Web of Science ®Google Scholar
• Preijers F. W. M. B., De Witte T., Wessels J. M. C., De Gast E. C., Van Leeuwen E., Capel P. J. A., Haanen C. Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WT1)-ricin A immunotoxin in T-cell lymphoblastic Leukemia and lymphoma. Blood 1989; 74: 1152–1158
   PubMed Web of Science ®Google Scholar
• Haas R., Kiesel S., Tweedale N., Yamal N., Korbling M., Dorken B., Hunstein W., Messner H. A new immunotoxin HD 37-ricin A conjugate for the purging of bone marrow for autologous transplantation in patients with B-cell malignancies. Blut 1986; 53: 185
   Google Scholar
• Gorin N. C., Douay L., Laporte J. P., Lopez M., Zittoun R., Rio B., David R., Stachowiak J., Jansen J., Casellas P., Pocelet P., Liance M. C., Voisin G. A., Salmon C., LeBlanc G., Deloux J., Najman A., Duhamel G. Autologous bone marrow transplantation with marrow decontaminated by immunotoxin T101 in the treatment of Leukemia and lymphoma: first clinical observations. Cancer Treatment Reports 1985; 69: 953–958
   PubMedGoogle Scholar
• Dillman R. O., Shawler D. L., Dillman J. B., Royston I. Therapy of chronic lymphocytic Leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. Journal of Clinical Oncology 1984; 2: 881–891
   PubMed Web of Science ®Google Scholar
• Schroff F. W., Farell M. M., Klein R. A., Oldham R. K., Foon K. A. T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic Leukemia patients. Journal of Immunology 1984; 133: 1641–1648
   PubMed Web of Science ®Google Scholar
• Blakey D. C., Watson G. J., Knowles P. P., Thorpe P. E. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy-1.1 antibody. Cancer Research 1987; 47: 947–952
   PubMed Web of Science ®Google Scholar
• Worrell N. R., Cumber A. J., Parnell G. D., Mirza P. A., Forrester J. A., Ross W. C. J. Fate of an antibody-ricin A conjugate administered to normal rats. Biochemistry and Pharmacology 1986; 35: 417–423
   PubMed Web of Science ®Google Scholar
• Wawrzynczak E. J., Cumber A. J., Henry R. V., Parnell G. D. Comparative biochemical, cytotoxic and pharmacokinetic properties of immunotoxins made with native ricin A chain, ricin A1 chain and recombinant ricin A chain. International Journal of Cancer 1991; 47: 130–135
   PubMed Web of Science ®Google Scholar
• Blakey D. C., Skilleter D. N., Price R. J., Thorpe P. E. Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo. Biochimica et Biophysica Acta 1988; 968: 172–178
   PubMed Web of Science ®Google Scholar
• Thorpe P. E., Wallace P. M., Knowles P. P., Relf M. G., Brown A. N. F., Watson G. J., Knyba R. E., Wawrzynczak E. J., Blakey D. C. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Research 1987; 47: 5924–5931
   PubMed Web of Science ®Google Scholar
• Thorpe P. E., Wallace P. M., Knowles P. P., Relf M. G., Brown A. N. F., Watson G. J., Blakey D. C., Newell D. R. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A chain and hindered disulfide linkages. Cancer Research 1988; 48: 6396–6403
   PubMed Web of Science ®Google Scholar
• Fulton R. J., Tucker T. F., Vitetta E. S., Uhr J. W. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization. Cancer Research 1988; 48: 2618–2625
   PubMed Web of Science ®Google Scholar
• Derocq J.-M., Casellas P., Laurent G., Ravel S., Vidal H., Jansen F. K. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins. Journal of Immunology 1988; 141: 2837–2843
   PubMed Web of Science ®Google Scholar
• Hertler A. A., Frankel A. E. Immunotoxins: a clinical review of their use in the treatment of malignancies. Journal of Clinical Oncology 1989; 7: 1932–1942
   PubMed Web of Science ®Google Scholar
• Pai L. H., FitzGerald D. J., Tepper M., Schacter B., Spitalny G., Pastan I. Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Research 1990; 50: 7750–7753
   PubMed Web of Science ®Google Scholar
• Hertler A. A., Schlossman D. M., Borowitz M. J., Blythman H. E., Casellas P., Frankel A. E. An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin. International Journal of Cancer 1989; 43: 215–219
   PubMed Web of Science ®Google Scholar
• Pearson J. W., Hedrick E., Fogler W. E., Bull R. L., Ferris D. K., Riggs C. W., Wiltrout R. H., Sivam G., Morgan A. C., Groves E., Longo D. L. Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant α-interferon. Cancer Research 1990; 50: 6379–6388
   PubMed Web of Science ®Google Scholar
• Yokota S., Hara H., Luo Y., Seon B. K. Synergistic potentiation of in vivo antitumor activity of anti-human T-Leukemia immunotoxins by recombinant a-interferon and daunorubicin. Cancer Research 1990; 50: 32–37
   PubMed Web of Science ®Google Scholar
• Oratz R., Speyer J. L., Wernz J. C., Hochster H., Meyers M., Mischak R., Spitler L. E. Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastic malignant melanoma: results of a phase II trial. Journal of Biological Response Modifiers 1990; 9: 345–354
   PubMedGoogle Scholar
• Vallera D. A., Carroll S. F., Snover D. C. Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier. Blood 1991; 77: 182–194
   PubMed Web of Science ®Google Scholar
• Kernan N. A., Byers V. B., Scannon P. J., Mischak R. P., Brochstein J., Flomenberg N., Dupont B., O'Reilly J. Treatment of steroid resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin. Journal of the American Medical Association 1988; 259: 3154–3157
   PubMed Web of Science ®Google Scholar
• Byers V., Henslee J., Kernan N. Therapeutic response to a pan T-lymphocyte monoclonal antibody-ricin A chain immunotoxin in steroid refractory graft versus host disease (GVHD). Int. Symposium on Immunotoxins, A. E. Frankel, 1988; 50, Durham, NC
   Google Scholar
• Rostaing-Capaillon O., Casellas P. Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxins in vivo. Cancer Research 1990; 50: 2909–2916
   PubMed Web of Science ®Google Scholar
• Wawrzynczak E. J., Henry R. V., Cumber A. J., Parnell G. D., Derbyshire E. J., Ulbrich N. Biochemical, cytotoxic and pharmacokinetic properties of an immunotoxin composed of a mouse monoclonal antibody Fib 75 and the ribosome-inactivating protein a-sarcin from Aspergillus giganteus. European Journal of Biochemistry 1991; 196: 203–209
   PubMedGoogle Scholar
• Oosterhout Y. V. J. M., Preijers F. W. M. B., Wessels J. M. C., De Witte T. 1992, Cytotoxicity of CD3-ricin A chain immunotoxins in relation to cellular uptake and degradation kinetics. Cancer Research52, in press
   Google Scholar